Actuate enters public market with front-line treatment for metastatic pancreatic cancer | $ACTU
Physicians unfortunately diagnose pancreatic ductal adenocarcinoma patients only when they express metastatic disease (mPDAC). As a result, advancing new mPDAC treatments remains a high priority for drug developers and mPDAC families. The 5-year survival rate in mPDAC is less than 10%.
Relying on the decades-old cancer target glycogen synthase kinase-3 (GSK-3), recently listed Actuate Therapeutics, Inc. (NASDAQ:ACTU) developed the small molecule elraglusib as a potential first-line treatment for mPDAC. The enzyme GSK-3 beta (GSK-3β) is highly expressed in pancreatic cancer and appears to cause tumor cells to resist conventional cancer therapy. Actuate designed elraglusib to enter cancer cells and block the function of GSK-3β. After testing elraglusib in different cancers in early clinical studies, the 9-year-old company identified pancreatic cancer as the most promising indication for elraglusib.
Key catalysts
Data from part 3B of phase II trial testing elraglusib to treat metastatic pancreatic cancer
Key catalyst dates
1Q 2025
—
